Statements (60)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:drug
|
gptkbp:bfsLayer |
6
|
gptkbp:bfsParent |
gptkb:Lansoprazole
gptkb:Protonix gptkb:Nexium_IV gptkb:Propranolol |
gptkbp:activities |
Inhibits Na+/ K+ AT Pase
|
gptkbp:affects |
Contractility
Heart rate |
gptkbp:appointed_by |
gptkb:hospital
gptkb:Company Healthcare professional |
gptkbp:approves |
1950s
|
gptkbp:brand |
gptkb:Lanoxin
Digitek |
gptkbp:caused_by |
Digoxin toxicity
|
gptkbp:contraindication |
Ventricular fibrillation
Hypersensitivity to digoxin |
gptkbp:developed_by |
Foxglove plant
|
gptkbp:discovered_by |
gptkb:19th_century
|
gptkbp:excretion |
Kidneys
|
https://www.w3.org/2000/01/rdf-schema#label |
Digoxin
|
gptkbp:ingredients |
C41 H64 O14
|
gptkbp:interacts_with |
gptkb:Amiodarone
gptkb:Quinidine gptkb:Verapamil Diuretics |
gptkbp:is_atype_of |
C01 A A05
|
gptkbp:is_available_on |
Injection
Oral tablet |
gptkbp:is_considered |
Essential medicine by WHO
|
gptkbp:is_monitored_by |
Electrolytes
Serum levels |
gptkbp:is_part_of |
Cardiac treatment regimen
|
gptkbp:is_subject_to |
Clinical guidelines
Drug interactions Regulatory approval Dosage adjustments Prescription requirements |
gptkbp:is_used_for |
Heart failure
Atrial fibrillation |
gptkbp:is_used_in |
gptkb:cemetery
Pediatric cardiology Geriatric medicine |
gptkbp:mass |
780.94 g/mol
|
gptkbp:metabolism |
Liver
|
gptkbp:side_effect |
gptkb:Nausea
Dizziness Vomiting Visual disturbances |
gptkbp:suitable_for |
Pregnant women
Patients with electrolyte imbalances Patients with renal impairment Patients with thyroid disorders |
gptkbp:symptoms |
Bradycardia
Arrhythmias Digoxin toxicity |
gptkbp:treatment |
Atrial flutter
Heart failure with reduced ejection fraction |
gptkbp:type_of |
20830-75-5
|